Patient characteristics (N = 400)
Characteristic . | No. (%) . |
---|---|
Median patient age at initial treatment, range, years | 52 (1-79) |
Patient gender | |
Male | 220 (55) |
Female | 180 (45) |
Donor-patient gender combination | |
Female to male | 108 (27) |
Other | 292 (73) |
Diagnosis | |
Myeloid malignancy | 232 (58) |
Lymphoid malignancy | 154 (39) |
Other/nonmalignant | 14 (4) |
Disease risk at transplantation* | |
Low | 136 (34) |
High | 264 (66) |
Conditioning regimen | |
High dose without TBI | 137 (34) |
High dose with TBI | 81 (20) |
Reduced intensity | 182 (46) |
Graft source | |
Bone marrow | 46 (12) |
Mobilized blood cells | 332 (83) |
Cord blood | 22 (6) |
Donor and HLA type | |
HLA-matched related | 147 (37) |
HLA-matched unrelated | 155 (39) |
HLA antigen or allele-mismatched related | 19 (5) |
HLA antigen or allele-mismatched unrelated | 79 (20) |
Characteristic . | No. (%) . |
---|---|
Median patient age at initial treatment, range, years | 52 (1-79) |
Patient gender | |
Male | 220 (55) |
Female | 180 (45) |
Donor-patient gender combination | |
Female to male | 108 (27) |
Other | 292 (73) |
Diagnosis | |
Myeloid malignancy | 232 (58) |
Lymphoid malignancy | 154 (39) |
Other/nonmalignant | 14 (4) |
Disease risk at transplantation* | |
Low | 136 (34) |
High | 264 (66) |
Conditioning regimen | |
High dose without TBI | 137 (34) |
High dose with TBI | 81 (20) |
Reduced intensity | 182 (46) |
Graft source | |
Bone marrow | 46 (12) |
Mobilized blood cells | 332 (83) |
Cord blood | 22 (6) |
Donor and HLA type | |
HLA-matched related | 147 (37) |
HLA-matched unrelated | 155 (39) |
HLA antigen or allele-mismatched related | 19 (5) |
HLA antigen or allele-mismatched unrelated | 79 (20) |
TBI, total body irradiation.
The low-risk category included chronic myeloid leukemia in chronic phase, acute leukemia in first remission, myelodysplastic syndrome without excess blasts, and nonmalignant diseases. The high-risk category included all other diseases and stages.